Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway

Multiple myeloma (MM) was characterized by frequent mutations in KRAS/NRAS/BRAF within the EGFR pathway that could induce resistance to EGFR inhibitors. We here report that EGFR inhibition solely exhibited moderate inhibition in KRAS/NRAS/BRAF wildtype (triple-WT) MM cells, whilst had no effect in myeloma cells with any of the mutated genes. The moderate inhibitory effect was conferred by induction of pentose phosphate pathway (PPP) when cells were treated with Gefitinib, the EGFR inhibitor. Combination of Gefitinib with PPP inhibitor 6AN effected synergistically in triple-WT cells. The inhibition could be restored by addition of NADPH. Dual EGFR/ERBB2 inhibitor Afatinib also exhibited similar effects. Further genetic silencing of EGFR, ERBB2 and mTOR indicated that major effect conferred by ERBB2 was via convergence to EGFR pathway in MM. Our results contributed to the individualized targeted therapy with EGFR inhibitors in MM.

[1]  A. Zaniboni,et al.  The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies. , 2014, Reviews on recent clinical trials.

[2]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[3]  D Puthier,et al.  High incidence of N and K‐Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis , 2001, Human mutation.

[4]  M. Oken,et al.  Activating Mutations of Nand Kras in Multiple Myeloma Show Different Clinical Associations : Analysis of the Eastern Cooperative Oncology Group Phase I 11 Trial , 2002 .

[5]  Gerald C. Chu,et al.  Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.

[6]  Laurence Lodé,et al.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Vij,et al.  Targeted treatments for multiple myeloma: specific role of carfilzomib , 2015, Pharmacogenomics and personalized medicine.

[8]  C. Sempoux,et al.  Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer , 2015, Targeted Oncology.

[9]  G. V. van Dongen,et al.  Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors. , 2014, Nuclear medicine and biology.

[10]  Joshua D. Rabinowitz,et al.  The return of metabolism: biochemistry and physiology of the pentose phosphate pathway , 2014, Biological reviews of the Cambridge Philosophical Society.

[11]  J. Kolesar,et al.  Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer. , 2014, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[12]  B. Ness,et al.  Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. , 1996, Blood.

[13]  A. Choi,et al.  Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide , 2013, Molecular Cancer Research.

[14]  N. Suzuki,et al.  Astroglial pentose phosphate pathway rates in response to high-glucose environments , 2012, ASN neuro.

[15]  A. Fernández-Medarde,et al.  Ras in cancer and developmental diseases. , 2011, Genes & cancer.

[16]  Shuji Ogino,et al.  NRAS Mutations Are Rare in Colorectal Cancer , 2010, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[17]  R. Finn,et al.  KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition , 2014, British Journal of Cancer.

[18]  G. Ahmann,et al.  Effect of Tissue Shipping on Plasma Cell Isolation, Viability, and RNA Integrity in the Context of a Centralized Good Laboratory Practice–Certified Tissue Banking Facility , 2008, Cancer Epidemiology Biomarkers & Prevention.

[19]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[20]  H. Lehrach,et al.  The pentose phosphate pathway is a metabolic redox sensor and regulates transcription during the antioxidant response. , 2011, Antioxidants & redox signaling.

[21]  A. Bardelli,et al.  Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer , 2014, Science Translational Medicine.

[22]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[23]  J. Hothersall,et al.  Inhibition of NADPH supply by 6‐aminonicotinamide: effect on glutathione, nitric oxide and superoxide in J774 cells , 1998, FEBS letters.

[24]  E. Høgdall,et al.  KRAS and BRAF mutations in anal carcinoma , 2015, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[25]  H. Avet-Loiseau,et al.  The impact of genomics on the management of myeloma. , 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

[26]  J. Shaughnessy,et al.  Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. , 2011, Blood.

[27]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[28]  R. Laing,et al.  Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer , 2014, Clinical Cancer Research.

[29]  Jie-wen Peng,et al.  Elevated neutrophil‐to‐lymphocyte ratio predicts poor outcome in patients with advanced non‐small‐cell lung cancer receiving first‐line gefitinib or erlotinib treatment , 2017, Asia-Pacific journal of clinical oncology.

[30]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[31]  A. McKenna,et al.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.

[32]  D. Kwiatkowski,et al.  Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent , 2011, Proceedings of the National Academy of Sciences.

[33]  Eric P. Smith,et al.  Physiologic Concepts That May Revise the Interpretation and Implications of HbA1C in Clinical Medicine , 2015, Journal of diabetes science and technology.

[34]  William Pao,et al.  Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 , 2012, Proceedings of the National Academy of Sciences.